Goldman Sachs Lawsuit Filed by SEC Over Abacus Fraud

The U.S. Securities and Exchange Commission (SEC) has filed a lawsuit against Goldman, Sachs & Co. charging the financial institution with fraud for allegedly selling investors subprime mortgage securities that were doomed to fail. 

The SEC filed the Goldman Sachs fraud lawsuit on April 16 in U.S. District Court for the Southern District of New York, following an investigation that started in August 2008. The SEC claims that fraud involving Abacus investment products lead to at least $1 billion in losses and many analysts predict that the charges will lead to a number of financial fraud lawsuits from investors who may be entitled to a recovery.

According to the SEC, Goldman Sachs created a synthetic collateralized debt obligation (CDO), called Abacus 2007-AC1, which was backed by subprime mortgage securities. The SEC claims that Goldman Sachs said that the securities were selected by a third party called ACA. However, the SEC says that Paulson & Co., a hedge fund that was betting on the failure of subprime mortgage securities, heavily influenced which securities went into the portfolio.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The charges claim that Paulson picked securities doomed to fail, and Goldman Sachs packaged them and sold them to unwitting investors. Paulson bet on the securities failing and made $1 billion. Those who bought into Abacus on the belief that it was a sound investment lost about $1 billion.

Goldman Sachs pocketed about $15 million from Paulson in the deal, the SEC alleges. The Royal Bank of Scotland and IKB, a German bank, were the two investment banks who lost the most from the deal, various media sources reported over the weekend.

The SEC says that the deal was primarily structured by Goldman Sachs vice president Fabrice Tourre, who allegedly knew that Paulson was structuring its investment plans based on the belief that the securities it chose for the portfolio would fail. Tourre closed the deal with Paulson to create Abacus on April 26, 2007, the SEC claims. By late October, 83% of the securities in the CDO had been downgraded. By the end of January 2008, 99% had been downgraded.

“The product was new and complex, but the deception and conflicts are old and simple,” said the SEC’s Director of Enforcement, Robert Khuzami. “Goldman wrongly permitted a client that was betting against the mortgage market to heavily influence which mortgage securities to include in an investment portfolio, while telling other investors that the securities were selected by an independent, objective third party.”

Goldman Sachs released a statement after the charges were released denying all of the SEC’s claims. The company claims it lost $90 million in the deal and fully disclosed Paulson & Co.’s involvement.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S.
Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S. (Posted 3 days ago)

A recently filed Depo-Provera lawsuit questions why Pfizer updated the drug label in Europe, to warn about the risk of meningioma brain tumors, but failed to provide the same Depo-Provera warnings to U.S. consumers and doctors.